FOOD AND DRUG ADMINISTRATION

CENTER FOR BIOLOGICS EVALUATION AND RESEARCH

 VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE

 MEETING ON INFLUENZA VIRUS VACCINE FORMULATION FOR 2002-2003 AND CBER LABORATORY SITE VISIT FOR LHV AND LVBVD

MEETING BY TELECONFERENCE
AGENDA
WEDNESDAY, MARCH 6, 2002
BUILDING 29, ROOM 121
Bethesda, Maryland
12:30 PM EST

Draft Agenda

12:30 PM Call to Order Dr. Daum, Committee Chair
12:35 Announcements Dr. Jody Sachs, FDA
12:40   Session 1- Open Session  

Strain Selection for the Influenza Virus Vaccine for 2002-2003

  Introduction and Review Dr. Levandowski, FDA
  Additional Information, A H3N2 and B Viruses Dr. Nancy Cox, CDC
Dr. Levandowski, FDA
1:30 Committee Discussion  
2:00 Open Public Hearing for Session 1  
 2:30 Recommendations for Influenza Virus Vaccine for 2002-2003
2:45  Session 2- Open Session  

Brief Overview of the CBER Laboratories that underwent Site Visit:

  Overview of the Division of Viral Products Dr. Jerry Weir
2:50 Synopsis of Laboratory of Hepatitis Virus (LHV)  Dr. Stephen Feinstone
3:05 Synopsis of Laboratory of Vector-borne Viral Diseases (LVVD) Dr. Lewis Markoff
3:20 Open Public Hearing for Session 2  
3:50 Session 3- Closed Session   Dr. Stanley Lemon

Site Visit Report Discussion and Committee Recommendations

4:50 Adjournment